Drug Development Pharma - August 27, 2021
TILT Biotherapeutics announces publication of pre-clinical data
New preclinical data relating to the use of the company’s oncolytic immunotherapy platform for expressing a human IL-2 variant protein has been published in Frontiers in Immunology. The paper was independently authored by researchers at the University of Helsinki and other leading institutions, together with TILT Biotherapeutics. TILT-452 The paper describes a study with TILT-452, […]
Clinical Trials - June 15, 2020
Immunicum advances its Phase Ib/II combination trial
Immunicum has announced that the sixth patient has completed the safety period in the ongoing Phase Ib/II ILIAD combination trial with ilixadencel, the company’s cell-based, off-the-shelf immune primer for the treatment of solid tumors. The Dose Escalation Committee (DEC) confirmed there were no dose limiting toxicities, therefore the study can move into the non-staggered inclusion […]
Clinical Trials - June 15, 2020
Affibody terminates program and announces positive data from another
Affibody has announced the completion of the ABY-039 Phase 1 trial, and the termination of the ABY-039 program due to tolerability observations that would limit the target product profile of subcutaneous high dose once monthly maintentance injections. Based on these observations Alexion has terminated the co-development agreement with Affibody. The termination will become effective June […]
Drug Development Pharma - May 19, 2020
Betalutin receives positive EMA opinion
Nordic Nanovector has announced that Betalutin (177Lu lilotomab satetraxetan) has received a positive opinion from the European Medicines Agency (EMA) on the application for orphan drug designation for the treatment of marginal zone lymphoma (MZL). The positive opinion is expected to be adopted by the European Commission shortly states the company. “We are very pleased […]
Drug Development Pharma - May 18, 2020
Oncopeptides announces new data
Oncopeptides has announced that data from the phase 2 study HORIZON, and additional clinical and preclinical data that further evaluate the therapeutic peptide-drug conjugate platform, have been accepted by the European Hematology Association (EHA). “The primary read-out of the HORIZON-data represents an important milestone for Oncopeptides. They lay the ground for the New Drug Application […]
Drug Development Pharma - May 5, 2020
Sprint Bioscience announces positive data
Sprint Bioscience has announced that a new scientific study with positive data concerning the company’s lead compound SB02024 has been published in Science Advances. The research results show that SB02024 activates the immune system in tumors in malignant melanoma and colorectal cancer. Sprint Bioscience is thus first in the world to demonstrate that inhibition of […]
